These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27374030)

  • 1. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
    Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
    Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed AML.
    Shimizu H; Yokohama A; Ishizaki T; Hatsumi N; Takada S; Saitoh T; Sakura T; Nojima Y; Handa H
    Hematol Oncol; 2018 Feb; 36(1):252-257. PubMed ID: 28378367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
    Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Specchia G; Lefrere F; Sica S; Mancini M; Venditti A; Hagemeijer A; Becker H; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
    Ann Hematol; 2018 Oct; 97(10):1785-1795. PubMed ID: 29926156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic and cytogenetic changes in acute leukaemia at relapse.
    Hur M; Chang YH; Lee DS; Park MH; Cho HI
    Clin Lab Haematol; 2001 Jun; 23(3):173-9. PubMed ID: 11553058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
    Klein K; Beverloo HB; Zimmermann M; Raimondi SC; von Neuhoff C; de Haas V; van Weelderen R; Cloos J; Abrahamsson J; Bertrand Y; Dworzak M; Fynn A; Gibson B; Ha SY; Harrison CJ; Hasle H; Elitzur S; Leverger G; Maschan A; Razzouk B; Reinhardt D; Rizzari C; Smisek P; Creutzig U; Kaspers GJL
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29341. PubMed ID: 34532968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
    Li X; Du W; Liu W; Li X; Li H; Huang SA
    APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunophenotyping in adult acute myeloid leukemia: which prognostic value?].
    Ben Salah N; Gouider E; Aounallah Skhiri H; El Borgi W; Jouabli M; Ben Lakhal F; Jeddi R; Hafsia R
    Tunis Med; 2012; 90(8-9):602-5. PubMed ID: 22987373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
    Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
    Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases posttherapy.
    Zheng J; Du W; Yao J; You Y; Li W; He Y; Li X; Liu W; Wu Y; Hu Y; Jin R; Zou P; Huang S; Hu Y; Zhang M
    Eur J Clin Invest; 2013 Nov; 43(11):1140-6. PubMed ID: 23992300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.
    Ouyang J; Goswami M; Tang G; Peng J; Ravandi F; Daver N; Routbort M; Konoplev S; Lin P; Medeiros LJ; Jorgensen JL; Wang SA
    Am J Hematol; 2015 Jun; 90(6):504-10. PubMed ID: 25732229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse.
    Garson OM; Hagemeijer A; Sakurai M; Reeves BR; Swansbury GJ; Williams GJ; Alimena G; Arthur DC; Berger R; de la Chapelle A
    Cancer Genet Cytogenet; 1989 Jul; 40(2):187-202. PubMed ID: 2766243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse.
    Reif SW; Wiesner D; Duell T; Mittermueller J; Schmetzer HM
    Eur J Haematol; 2001 Oct; 67(4):207-20. PubMed ID: 11860441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
    Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
    Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.